Drug induced QT prolongation.

The drug-induced QT prolongation predisposes to development of torsades de pointes (TdP) ventricular tachycardia and sudden death. The association between specific drug and development of TdP is difficult to document, therefore, QT prolongation is considered as a surrogate marker of the proarrhythmia risk. Most of the drugs prolong QT interval usually by blocking the potassium IKr current or altering trafficking of proteins forming the channel. Improved understanding of ion channel structure and kinetics and its role in repolarization has tremendous impact on understanding of the mechanisms of drug-induced QT prolongation and TdP. Proarrhythmia caused by a QT-prolonging drug occurs infrequently, and usually multiple factors need to operate to precipitate such an event including a combination of two or more drugs affecting the same pathway, hypokalemia, and possibly genetic predisposition. ECG provides unique opportunity to ensure safety of administered therapy. QT measurement is the most routine approach to a drug safety monitoring, however, there are many challenges related to methodology of measurements, accuracy of measurements, or optimal heart rate correction. Since drugs affecting repolarization not only prolong QT but also they alter T wave morphology, novel computerized methods quantifying these changes are being developed to assist physicians and drug manufacturers in monitoring safety of the drugs. The response of a patient to a drug is very individual and therefore an individualized system of drug administration and monitoring needs to be developed, which takes into account baseline QTc duration and its changes after a drug was introduced. (Cardiol J 2007; 14: 523-533).

[1]  Wataru Shimizu,et al.  Cellular mechanisms underlying the long QT syndrome. , 2002, Current opinion in cardiology.

[2]  D M Roden,et al.  A common polymorphism associated with antibiotic-induced cardiac arrhythmia. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[3]  C Antzelevitch,et al.  The potential for QT prolongation and proarrhythmia by non-antiarrhythmic drugs: clinical and regulatory implications. Report on a policy conference of the European Society of Cardiology. , 2000, European heart journal.

[4]  Christian Gieger,et al.  A common genetic variant in the NOS1 regulator NOS1AP modulates cardiac repolarization , 2006, Nature Genetics.

[5]  H. Mabuchi,et al.  T wave peak-to-end interval and QT dispersion in acquired long QT syndrome: a new index for arrhythmogenicity. , 2003, Clinical science.

[6]  J. Stockman.  Genetic Testing in the Long QT Syndrome: Development and Validation of an Efficient Approach to Genotyping in Clinical Practice , 2007 .

[7]  Control of rapid heart rate changes for electrocardiographic analysis: implications for thorough QT studies , 2006, Clinical cardiology.

[8]  Jeffrey B. Gross,et al.  Timing of New Black Box Warnings and Withdrawals for Prescription Medications , 2003 .

[9]  J. Karjalainen,et al.  Relation between QT intervals and heart rates from 40 to 120 beats/min in rest electrocardiograms of men and a simple method to adjust QT interval values. , 1994, Journal of the American College of Cardiology.

[10]  R. Temple,et al.  Safety of newly approved drugs: implications for prescribing. , 2002, JAMA.

[11]  A. Moss,et al.  ECG T-wave patterns in genetically distinct forms of the hereditary long QT syndrome. , 1995, Circulation.

[12]  Jason Lazarou,et al.  Incidence of Adverse Drug Reactions in Hospitalized Patients , 1999 .

[13]  Giuseppe Curigliano,et al.  Drug-induced prolongation of the QT interval. , 2004, The New England journal of medicine.

[14]  Wojciech Zareba,et al.  Dispersion of Repolarization: Time to Move Beyond QT Dispersion , 2000 .

[15]  C. Antzelevitch,et al.  Unique Topographical Distribution of M Cells Underlies Reentrant Mechanism of Torsade de Pointes in the Long-QT Syndrome , 2002, Circulation.

[16]  D M Roden,et al.  The long QT syndromes: genetic basis and clinical implications. , 2000, Journal of the American College of Cardiology.

[17]  M. Sanguinetti,et al.  A mechanistic link between an inherited and an acquird cardiac arrthytmia: HERG encodes the IKr potassium channel , 1995, Cell.

[18]  D. Roden,et al.  Incidence and clinical features of the quinidine-associated long QT syndrome: implications for patient care. , 1986, American heart journal.

[19]  S. Priori,et al.  Influence of the genotype on the clinical course of the long-QT syndrome. International Long-QT Syndrome Registry Research Group. , 1998, The New England journal of medicine.

[20]  P. Kowey,et al.  Blinded validation of the isolated arterially perfused rabbit ventricular wedge in preclinical assessment of drug-induced proarrhythmias. , 2006, Heart rhythm.

[21]  D. Levy,et al.  An improved method for adjusting the QT interval for heart rate (the Framingham Heart Study) , 1992, The American journal of cardiology.

[22]  Li Zhang,et al.  Inaccurate electrocardiographic interpretation of long QT: the majority of physicians cannot recognize a long QT when they see one. , 2005, Heart rhythm.

[23]  M. Sanguinetti,et al.  Molecular and Cellular Mechanisms of Cardiac Arrhythmias , 2001, Cell.

[24]  P. C. Viswanathan,et al.  Genetics of acquired long QT syndrome. , 2005, The Journal of clinical investigation.

[25]  Calum A MacRae,et al.  Risk stratification in the long-QT syndrome. , 2003, The New England journal of medicine.

[26]  M. Hodges.  Bazett's QT correction reviewed : Evidence that a linear QT correction for heart rate is better , 1983 .

[27]  D. Roden,et al.  Normalization of acquired QT prolongation in humans by intravenous potassium. , 1997, Circulation.

[28]  D. Roden.  Acquired Long QT Syndromes and the Risk of Proarrhythmia , 2000, Journal of cardiovascular electrophysiology.

[29]  Y Chen,et al.  Mechanism of the cardiotoxic actions of terfenadine. , 1993, JAMA.

[30]  C. Holstege,et al.  ECG manifestations: the poisoned patient. , 2006, Emergency medicine clinics of North America.

[31]  Borje Darpo,et al.  Identification of sotalol-induced changes in repolarization with T wave area-based repolarization duration parameters. , 2003, Journal of electrocardiology.

[32]  Panagiotis Korantzopoulos,et al.  Drug-induced prolongation of the QT interval. , 2004, The New England journal of medicine.

[33]  Wojciech Zareba,et al.  Repolarization morphology in adult LQT2 carriers with borderline prolonged QTc interval. , 2006, Heart rhythm.

[34]  A. Camm,et al.  Drug induced QT prolongation and torsades de pointes , 2003, Heart.

[35]  G. Kay,et al.  Torsade de pointes: the long-short initiating sequence and other clinical features: observations in 32 patients. , 1983, Journal of the American College of Cardiology.

[36]  H. Bazett,et al.  AN ANALYSIS OF THE TIME‐RELATIONS OF ELECTROCARDIOGRAMS. , 1997 .

[37]  M. Rosen.  Mechanisms of cardiac arrhythmias: focus on atrial fibrillation. , 2001, The journal of gender-specific medicine : JGSM : the official journal of the Partnership for Women's Health at Columbia.

[38]  D. Levy,et al.  Common Genetic Variation in KCNH2 Is Associated With QT Interval Duration: The Framingham Heart Study , 2007, Circulation.

[39]  J. Cummings,et al.  Quinidine Syncope: Paroxysmal Ventricular Fibrillation Occurring during Treatment of Chronic Atrial Arrhythmias , 1964, Circulation.

[40]  C. Benedict.  The QT Interval and Drug-Associated Torsades de Pointes , 1993 .

[41]  A. Moss,et al.  The Long QT Syndrome: Prospective Longitudinal Study of 328 Families , 1991, Circulation.

[42]  A. Hoes,et al.  In-hospital cardiac arrest is associated with use of non-antiarrhythmic QTc-prolonging drugs. , 2007, British journal of clinical pharmacology.

[43]  Andrew C. Zygmunt,et al.  Electrophysiological Effects of Ranolazine, a Novel Antianginal Agent With Antiarrhythmic Properties , 2004, Circulation.

[44]  J. Ruskin,et al.  Drug‐Induced Torsades de Pointes and Implications for Drug Development , 2004, Journal of cardiovascular electrophysiology.

[45]  M. Lehmann,et al.  Female gender as a risk factor for torsades de pointes associated with cardiovascular drugs. , 1993, JAMA.

[46]  Andrew J. Sauer,et al.  Long QT syndrome in adults. , 2007, Journal of the American College of Cardiology.

[47]  R. Prineas,et al.  Sex differences in the evolution of the electrocardiographic QT interval with age. , 1992, The Canadian journal of cardiology.

[48]  L. S. Fridericia,et al.  The Duration of Systole in an Electrocardiogram in Normal Humans and in Patients with Heart Disease * , 2003, Annals of noninvasive electrocardiology : the official journal of the International Society for Holter and Noninvasive Electrocardiology, Inc.

[49]  A J Moss,et al.  Clinical features of the idiopathic long QT syndrome. , 1992, Circulation.

[50]  D. Roden,et al.  Extracellular potassium modulation of drug block of IKr. Implications for torsade de pointes and reverse use-dependence. , 1996, Circulation.

[51]  D. Levy,et al.  Common Genetic Variation in KCNH 2 Is Associated With QT Interval Duration The Framingham Heart Study , 2007 .

[52]  K. Hayashi,et al.  T‐peak to T‐end interval may be a better predictor of high‐risk patients with hypertrophic cardiomyopathy associated with a cardiac troponin i mutation than qt dispersion , 2002, Clinical cardiology.

[53]  S le Cessie,et al.  Risk of cardiac events in family members of patients with long QT syndrome. , 1995, Journal of the American College of Cardiology.

[54]  W. Zareba,et al.  Antipsychotic Drugs and QT Interval Prolongation , 2004, Psychiatric Quarterly.

[55]  Robert M Califf,et al.  What clinicians should know about the QT interval. , 2003, JAMA.